Omeros (NASDAQ:OMER) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Omeros (NASDAQ:OMER) from a sell rating to a hold rating in a research note released on Monday.

Other analysts also recently issued reports about the stock. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Friday. D. Boral Capital reiterated a “buy” rating and set a $36.00 price target on shares of Omeros in a report on Tuesday, May 13th. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Up 3.4%

Shares of NASDAQ OMER opened at $3.32 on Monday. Omeros has a 12 month low of $2.97 and a 12 month high of $13.60. The company has a market cap of $193.58 million, a price-to-earnings ratio of -1.44 and a beta of 2.42. The business has a fifty day simple moving average of $6.97 and a 200-day simple moving average of $8.16.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.05). As a group, sell-side analysts expect that Omeros will post -3.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Truvestments Capital LLC grew its holdings in shares of Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 1,972 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Omeros in the 4th quarter valued at approximately $46,000. Picton Mahoney Asset Management increased its stake in shares of Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 4,404 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in Omeros by 14,486.3% during the first quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 7,388 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.